Unraveling the pathogenesis of Parkinson's disease - The contribution of monogenic forms

Cellular and Molecular Life Sciences

Volumn 61, Issue 14, 2004, Pages 1729-1750

  Bonifati, V ^a,b   Oostra, B A ^a   Heutink, P ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DJ 1; Genetics; Parkin; Parkinson's disease; Pathogenesis; PINK1; synuclein

Indexed keywords

CHAPERONE; HYDROLASE; PARKIN; PROTEIN; SYNPHILIN 1; TRANSCRIPTION FACTOR; UBIQUITIN; UNCLASSIFIED DRUG;

ALPHA SYNUCLEIN GENE; APOPTOSIS; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE DISORDER; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CLINICAL FEATURE; COMPLEX FORMATION; CORRELATION ANALYSIS; DISEASE COURSE; DROSOPHILA; GENE; GENE EXPRESSION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; MITOCHONDRION; MOLECULAR CLONING; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MONOGENIC DISORDER; NERVE DEGENERATION; NEUROIMAGING; NONHUMAN; PARKIN GENE; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION;

EID: 3843066722     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4104-1     Document Type: Review

References (278)

1. Lang A. E. and Lozano A. M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med. 339: 1044-1053
2. Gelb D. J., Oliver E. and Gilman S. (1999) Diagnostic criteria for Parkinson disease. Arch. Neurol. 56: 33-39
3. Rajput A. H., Rozdilsky B. and Rajput A. (1991) Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can. J. Neurol. Sci. 18: 275-278
4. Hughes A. J., Daniel S. E., Kilford L. and Lees A. J. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55: 181-184
5. Spira P. J., Sharpe D. M., Halliday G., Cavanagh J. and Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49: 313-319
6. Gasser T., Muller-Myhsok B., Wszolek Z. K., Oehlmann R., Calne D. B., Bonifati V. et al. (1998) A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet. 18: 262-265
7. Mori H., Kondo T., Yokochi M., Matsumine H., Nakagawa-Hattori Y., Miyake T. et al. (1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 51: 890-892
8. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S. and Obata F. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51: 296-301
9. Bonifati V., Oostra B. A. and Heutink P. (2004) Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. J. Mol. Med. 82: 163-174
10. Bonifati V. and Heutink P. (2004) Chromosome 1 and other hotspots for Parkinson's disease genes. In: Molecular Mechanisms of Parkinson's disease, Kahle P. and Haass C. (eds), Eurekah.com, (available at PubMed Book Shelf)
11. Golbe L. I., Di Iorio G., Bonavita V., Miller D. C. and Duvoisin R. C. (1990) A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol. 27: 276-282
12. Golbe L. I., Di Iorio G., Sanges G., Lazzarini A. M., La Sala S., Bonavita V et al. (1996) Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann. Neurol. 40: 767-775
13. Polymeropoulos M. H., Higgins J. J., Golbe L. I., Johnson W. G., Ide S. E., Di Iorio G. et al. (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274: 1197-1199
14. Scott W. K., Staijich J. M., Yamaoka L. H., Speer M. C., Vance J. M., Roses A. D. et al. (1997) Genetic complexity and Parkinson's disease. Science 277: 387-388
15. Gasser T., Muller-Myhsok B., Wszolek Z. K., Durr A., Vaughan J. R., Bonifati V. et al. (1997) Genetic complexity and Parkinson's disease. Science 277: 388-389
16. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
17. Athanassiadou A., Voutsinas G., Psiouri L., Leroy E., Polymeropoulos M. H., Ilias A. et al. (1999) Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. Hum. Genet. 65: 555-558
18. Markopoulou K., Wszolek Z. K., Pfeiffer R. F. and Chase B. A. (1999) Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann. Neurol. 46: 374-381
19. Papapetropoulos S., Paschalis C., Athanassiadou A., Papadimitriou A., Ellul J., Polymeropoulos M. H. et al. (2001) Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70: 662-665
20. Bostantjopoulou S., Katsarou Z., Papadimitriou A., Veletza V, Hatzigeorgiou G. and Lees A. (2001) Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov. Disord. 16: 1007-1013
21. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S. et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18: 106-108
22. Vaughan J., Durr A., Tassin J., Bereznai B., Gasser T., Bonifati V. et al. (1998) The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. Ann. Neurol. 44: 270-273
23. Vaughan J. R., Farrer M. J., Wszolek Z. K., Gasser T., Durr A., Agid Y. et al. (1998) Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. Hum. Mol. Genet. 7: 751-753
24. Chan P., Jiang X., Forno L. S., Di Monte D. A., Tanner C. M. and Langsten J. W. (1998) Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology 50: 1136-1137
25. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840
26. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95: 6469-6473
27. Wakabayashi K., Yoshimoto M., Tsuji S. and Takahashi H. (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249: 180-182
28. Spillantini M. G. and Goedert M. (2000) The alpha-synuclein-opathies: Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Ann. N. Y. Acad. Sci. 920: 16-27
29. Feany M. B. and Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404: 394-398
30. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A. et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287: 1265-1269
31. van der Putten H., Wiederhold K. H., Probst A., Barbieri S., Mistl C., Danner S. et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20: 6021-6029
32. Kahle P. J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A. et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20: 6365-6373
33. Lee M. K., Stirling W., Xu Y., Xu X., Qui D., Mandir A. S. et al. (2002) Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53-Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99: 8968-8973
34. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q. and Lee V. M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 34: 521-533
35. Lakso M., Vartiainen S., Moilanen A. M., Sirvio J., Thomas J. H., Nass R. et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86: 165-172
36. Touchman J. W., Dehejia A., Chiba-Falek O., Cabin D. E., Schwartz J. R., Orrison B. M. et al. (2001) Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome. Res. 11: 78-86
37. Chiba-Falek O. and Nussbaum R. L. (2001) Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet 10: 3101-3109
38. Farrer M., Maraganore D. M., Lockhart P., Singleton A., Lesnick T. G., de Andrade M. et al. (2001) alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10: 1847-1851
39. Duda J. E., Giasson B. I., Mabon M. E., Miller D. C., Golbe L. I., Lee V. M. et al. (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta. Neuropathol. (Berl) 104: 7-11
40. Kruger R., Kuhn W., Leenders K. L., Sprengelmeyer R., Muller T., Woitalla D. et al. (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 56: 1355-1362
41. Zarranz J. J., Alegre J., Gomez-Esteban J. C., Lezcano E., Ros R., Ampuero I. et al. (2004) The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. Ann. Neurol. 55: 164-173
42. Singleton A. B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841
43. Farrer M., Gwinn-Hardy K., Muenter M., DeVrieze F. W., Crook R., Perez-Tur J. et al. (1999) A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum. Mol. Genet. 8: 81-85
44. Farrer M., Kachergus J., Forno L-, Lincoln S-, Wang D. S., Hulihan M. et al. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55: 174-179
45. Waters C. H. and Miller C. A. (1994) Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann. Neurol. 35: 59-64
46. Muenter M. D., Forno L. S., Hornykiewicz O., Kish S. J., Maraganore D. M., Caselli R. J. et al. (1998) Hereditary form of parkinsonism - dementia. Ann. Neurol. 43: 768-781
47. Gwinn-Hardy K., Mehta N. D., Farrer M., Maraganore D., Muenter M., Yen S. H. et al. (2000) Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta. Neuropathol. (Berl) 99: 663-672
48. Wszolek Z. K., Cordes M., Calne D. B., Munter M. D., Cordes I. and Pfeifer R. F. (1993) [Hereditary Parkinson disease: report of 3 families with dominant autosomal inheritance]. Nervenarzt 64: 331-335
49. Denson M. A., Wszolek Z. K., Pfeiffer R. F., Wszolek E. K., Paschall T. M. and McComb R. D. (1997) Familial parkinsonism, dementia and Lewy body disease: study of family G. Ann. Neurol. 42: 638-643
50. Wszolek Z. K., Gwinn-Hardy K., Wszolek E. K., Muenter M. D., Pfeiffer R. F., Rodnitzky R. L. et al. (2002) Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism. Acta. Neuropathol. 103: 344-350
51. West A. B., Zimprich A., Lockhart P. J., Farrer M., Singleton A., Holtom B. et al. (2001) Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. Eur. J. Hum. Genet. 9: 659-666
52. Zink M., Grim L., Wszolek Z. K. and Gasser T. (2001) Autosomal-dominant Parkinson's disease linked to 2p13 is not caused by mutations in transforming growth factor alpha (TGF alpha). J. Neural. Transm. 108: 1029-1034
53. Lockhart P. J., Holtom B., Lincoln S., Hussey J., Zimprich A., Gasser T. et al. (2002) The human sideroflexin 5 (SFXN5) gene: sequence, expression analysis and exclusion as a candidate for PARK3. Gene. 285: 229-237
54. DeStefano A. L., Lew M. F., Golbe L. I., Mark M. H., Lazzarini A. M., Guttman M. et al. (2002) PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am. J. Hum. Genet. 70: 1089-1095
55. Karamohamed S., DeStefano A. L., Wilk J. B., Shoemaker C. M., Golbe L. I., Mark M. H. et al. (2003) A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study. Neurology 61: 1557-1561
56. Wilkinson K. D., Lee K. M., Deshpande S., Duerksen-Hughes P., Boss J. M. and Pohl J. (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246: 670-673
57. Osaka H., Wang Y. L., Takada K., Takizawa S., Setsuie R., Li H. et al. (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 12: 1945-1958
58. Lowe J., McDermott H., Landon M., Mayer R. J. and Wilkinson K. D. (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161: 153-160
59. Saigoh K., Wang Y. L., Suh J. G., Yamanishi T., Sakai Y., Kiyosawa H. et al. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23: 47-51
60. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452
61. Lincoln S., Vaughan J., Wood N., Baker M., Adamson J., Gwinn-Hardy K. et al. (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 10: 427-429
62. Harhangi B. S., Farrer M. J., Lincoln S., Bonifati V., Meco G., De Michele G. et al. (1999) The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci. Lett. 270: 1-4
63. Zhang J., Hattori N., Giladi N. and Mizuno Y. (2000) Failure to find mutations in ubiquitin carboxy-terminal hydrolase L1 gene in familial Parkinson's disease. Parkinsonism Relat. Disord. 6: 199-200
64. Hoenicka J., Vidai L., Morales B., Ampuero I., Jimenez-Jimenez F. J., Berciano J. et al. (2002) Molecular findings in familial Parkinson disease in Spain. Arch. Neurol. 59: 966-970
65. Maraganore D. M., Farrer M. J., Hardy J. A., Lincoln S. J., McDonnell S. K. and Rocca W. A. (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53: 1858-1860
66. Wintermeyer P., Kruger R., Kuhn W., Muller T., Woitalla D., Berg D. et al. (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 11: 2079-2082
67. Zhang J., Hattori N., Leroy E., Morris H. R., Kubo S., Kobayashi T. et al. (2000) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat. Disord. 6: 195-197
68. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I. et al. (2002) Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 51: 133-136
69. Liu Y., Fallon L., Lashuel H. A., Liu Z. and Lansbury P. T. Jr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111: 209-218
70. Hasegawa K. and Kowa H. (1997) Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Eur. Neurol. 38: 39-43
71. Scott W. K., Grubber J. M., Conneally P. M., Small G. W., Hulette C. M., Rosenberg C. K. et al. (2000) Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am. J. Hum. Genet. 66: 922-932
72. Zimprich A., Muller-Myhsok B., Farrer M., Leitner P., Sharma M., Hulihan M. et al. (2004) The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am. J. Hum. Genet. 74: 11-19
73. Saucedo-Cardenas O. Kardon R. Ediger T. R., Lydon J. P. and Conheely O. M. (1997) Cloning and structural organization of the gene encoding the murine nuclear receptor transcription factor, NURR1. Gene. 187: 135-139
74. Zetterstrom R. H., Solomin L., Jansson L., Hoffer B. J., Olson L. and Perlmann T. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science 276: 248-250
75. Rawal N., Periquet M., Durr A., de Michele G., Bonifati V., Teive H. A. et al. (2002) Exclusion of the Nurr1 gene in autosomal recessive Parkinson's disease. J. Neurol. 249: 1127-1129
76. Xu P. Y., Liang R., Jankovic J., Hunter C., Zeng Y. X., Ashizawa T et al. (2002) Association of homozygous 7048-G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 58: 881-884
77. Zheng K., Heydari B. and Simon D. K. (2003) A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch. Neurol. 60: 722-725
78. Tan E. K., Chung H., Zhao Y., Shen H., Chandran V. R., Tan C. et al. (2003) Genetic analysis of Nurr1 haplotypes in Parkinson's disease. Neurosci. Lett. 347: 139-142
79. Le W. D., Xu P., Jankovic J., Jiang H., Appel S. H., Smith R. G. et al. (2003) Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33: 85-89
80. Zimprich A., Asmus F., Leitner P., Castro M., Bereznai B., Homann N et al. (2003) Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease. Neurogenetics 4: 219-220
81. Wellenbrock C., Hedrich K., Schafer N., Kasten M., Jacobs H., Schwinger E. et al. (2003) NR4A2 mutations are rare among European patients with familial Parkinson's disease. Ann. Neurol. 54: 415
82. Nichols W. C., Uniacke S. K., Pankratz N., Reed T., Simon D. K., Halter C. et al. (2004) Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov. Disord., in press. Published Online: 16 Mar 2004. DOI: 10.1002/mds.20097
83. Engelender S., Kaminsky Z., Guo X., Sharp A. H., Amaravi R. K., Kleiderlein J. J. et al. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22: 110-114
84. Ribeiro C. S., Carneiro K., Ross C. A., Menezes J. R. and Engelender S. (2002) Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J Biol Chem 277: 23927-23933
85. Engelender S., Wanner T., Kleiderlein J. J., Wakabayashi K., Tsuji S., Takahashi H. et al. (2000) Organization of the human synphilin-1 gene, a candidate for Parkinson's disease. Mamm. Genome. 11: 763-766
86. Wakabayashi K., Engelender S., Tanaka Y., Yoshimoto M., Mori F., Tsuji S. et al. (2002) Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta. Neuropathol. (Berl) 103: 209-214
87. Murray I. J., Medford M. A., Guan H. P., Rueter S. M., Trojanowski J. Q. and Lee V. M. (2003) Synphilin in normal human brains and in synucleinopathies: studies with new antibodies. Acta. Neuropathol. (Berl) 105: 177-184
88. Chung K. K., Zhang Y., Lim K. L., Tanaka Y., Huang H., Gao J. et al. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7: 1144-1150
89. Scott W. K., Nance M. A., Watts R. L., Hubble J. P., Koller W C., Lyons K. et al. (2001) Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286: 2239-2244
90. Pankratz N., Nichols W. C., Uniacke S. K., Halter C., Rudolph A., Shults C. et al. (2002) Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am. J. Hum. Genet. 71: 124-135
91. Hicks A. A., Petursson H., Jonsson T., Stefansson H., Johannsdottir H. S., Sainz J. et al. (2002) A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52: 549-555
92. Marx F. P., Holzmann C., Strauss K. M., Li L., Eberhardt O., Gerhardt E. et al. (2003) Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 12: 1223-1231
93. Racette B. A., Rundle M., Wang J. C., Goate A., Saccone N. L., Farrer M. et al. (2002) A multi-incident, Old-Order Amish family with PD. Neurology 58: 568-574
94. Nicholl D. J., Vaughan J. R., Khan N. L., Ho S. L., Aldous D. E., Lincoln S. et al. (2002) Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. Brain 125: 44-57
95. Grimes D. A., Grimes J. D., Racacho L., Scoggan K. A., Han F., Schwarz B. A. et al. (2002) Large French-Canadian family with Lewy body parkinsonism: exclusion of known loci. Mov. Disord. 17: 1205-1212
96. Bertoli Avella A. M., Giroud Benitez J. L., Bonifati V., Alvarez Gonzalez E., Heredero Baute L., van Duijn C. M. et al. (2003) Suggestive linkage to chromosome 19 in a large Cuban family with late-onset Parkinson's disease. Mov. Disord. 18: 1240-1249
97. Yamamura Y., Sobue I., Ando K., Iida M., Yanagi T. (1973) Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 23: 239-244
98. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T. et al. (1994) Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44: 437-441
99. Ishikawa A., Tsuji S. (1996) Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 47: 160-166
100. Matsumine H., Saito M., Shimoda-Matsubayashi S., Tanaka H., Ishikawa A., Nakagawa-Hattori Y. et al. (1997) Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am. J. Hum. Genet. 60: 588-596
101. Tassin J., Durr A., de Broucker T., Abbas N., Bonifati V., De Michele G. et al. (1998) Chromosome 6-linked autosomal recessive early-onset Parkinsonism: linkage in European and Algerian families, extension of the clinical spectrum, and evidence of a small homozygous deletion in one family. Am. J. Hum. Genet. 63: 88-94
102. Jones A. C., Yamamura Y., Almasy L., Bohlega S., Elibol B., Hubble J. et al. (1998) Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am. J. Hum. Genet. 63: 80-87
103. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S. et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608
104. Kitada T., Asakawa S., Minoshima S., Mizuno Y. and Shimizu N. (2000) Molecular cloning, gene expression and identification of a splicing variant of the mouse parkin gene. Mamm. Genome. 11: 417-421
105. Mata I. F., Lockhart P. J. and Farrer M. J. (2004) Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet. 13: R127-133.
106. Lucking C. B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T. et al. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342: 1560-1567
107. Hedrich K., Kann M., Lanthaler A. J., Dalski A., Eskelson C., Landt O. et al. (2001) The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum. Mol. Genet. 10: 1649-1656
108. Foroud T., Uniacke S. K., Liu L., Pankratz N., Rudolph A., Halter C. et al. (2003) Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 60: 796-801
109. Periquet M., Lucking C., Vaughan J., Bonifati V., Durr A., De Michele G et al. (2001) Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from founder effects. Am. J. Hum. Genet. 68: 617-626
110. Lincoln S., Wiley J., Lynch T., Langsten J. W., Chen R., Lang A. et al. (2003) Parkin-proven disease: common founders but divergent phenotypes. Neurology 60: 1605-1610
111. Periquet M., Latouche M., Lohmann E., Rawal N., De Michele G., Ricard S. et al. (2003) Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 126: 1271-1278
112. Kann M., Jacobs H., Mohrmann K., Schumacher K., Hedrich K., Garrels J. et al. (2002) Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann. Neurol. 51: 621-625
113. Golbe L. I. (1991) Young-onset Parkinson's disease: a clinical review. Neurology 41: 168-173
114. Klein C., Pramstaller P. P., Kis B., Page C. C., Kann M, Leung J. et al. (2000) Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann. Neurol. 48: 65-71
115. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D. et al. (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50: 293-300
116. Khan N. L., Graham E., Critchley P., Schrag A. E., Wood N. W., Lees A. J. et al. (2003) Parkin disease: a phenotypic study of a large case series. Brain 126: 1279-1292
117. Maruyama M., Ikeuchi T., Saito M., Ishikawa A., Yuasa T., Tanaka H. et al. (2000) Novel mutations, pseudo-dominant inheritance and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann. Neurol. 48: 245-250
118. Lucking C. B., Bonifati V., Periquet M., Vanacore N., Brice A. and Meco G. (2001) Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations. Neurology 57: 924-927
119. Bonifati V., Lucking C. B., Fabrizio E., Periquet M., Meco G. and Brice A. (2001) Three parkin gene mutations in a sibship with autosomal recessive early onset parkinsonism. J. Neurol. Neurosurg. Psychiatry 71: 531-534
120. Kobayashi T., Matsumine H., Zhang J., Imamichi Y., Mizuno Y. and Hattori N. (2003) Pseudo-autosomal dominant inheritance of PARK2: two families with parkin gene mutations. J. Neurol. Sci. 207: 11-17
121. Hedrich K., Marder K., Harris J., Kann M., Lynch T., Meija-Santana H. et al. (2002) Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 58: 1239-1246
122. Lohmann E., Periquet M., Bonifati V., Wood NW., De Michele G., Bonnet A. M. et al. (2003) How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 54: 176-185
123. Asakawa S., Tsunematsu K., Takayanagi A., Sasaki T., Shimizu A., Shintani A. et al. (2001) The genomic structure and promoter region of the human parkin gene. Biochem. Biophys. Res. Commun. 286: 863-868
124. West A., Farrer M., Petrucelli L., Cookson M., Lockhart P. and Hardy J. (2001) Identification and characterization of the human parkin gene promoter. J. Neurochem. 78: 1146-1152
125. West A. B., Maraganore D., Crook J., Lesnick T., Lockhart P. J., Wilkes K. M. et al. (2002) Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Hum. Mol. Genet. 11: 2787-2792
126. Mata I. F., Alvarez V., Garcia-Moreira V., Guisasola L. M., Ribacoba R., Salvador C. et al. (2002) Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neurosci. Lett. 329: 149-152
127. Hattori N., Kitada T., Matsumine H., Asakawa S., Yamamura Y., Yoshino H. et al. (1998) Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann. Neurol. 44: 935-941
128. Abbas N., Lucking CB., Ricard S., Durr A., Bonifati V., De Michele G. et al. (1999) A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum. Mol. Genet. 8: 567-574
129. Wang M., Hattori N., Matsumine H., Kobayashi T., Yoshino H., Morioka A. et al. (1999) Polymorphism in the parkin gene in sporadic Parkinson's disease. Ann. Neurol. 45: 655-658
130. Oliveira S. A., Scott W. K., Nance M. A., Watts R. L., Hubble J. P., Koller W. C. et al. (2003) Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch. Neurol. 60: 975-980
131. Lucking C. B., Chesneau V., Lohmann E., Verpillat .P, Dulac C., Bonnet A. M. et al. (2003) Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch. Neurol. 60: 1253-1256
132. West A. B., Lockhart P. J., O'Farell C. and Farrer M. J. (2003) Identification of a novel gene linked to parkin via a bi-directional promoter. J. Mol. Biol. 326: 11-19
133. Imai Y., Soda M., Murakami T., Shoji M., Abe K. and Takahashi R. (2003) A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J. Biol. Chem. 278: 51901-51910.
134. West A., Periquet M., Lincoln S., Lucking C. B., Nicholl D., Bonifati V. et al. (2002) Complex relationship between Parkin mutations and Parkinson disease. Am. J. Med. Genet. 114: 584-591
135. Hilker R., Klein C., Ghaemi M., Kis B., Srrotmann T., Ozelius L. J. et al. (2001) Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann. Neurol. 49: 367-376
136. Khan N. L., Brooks D. I., Pavese N., Sweeney M. G., Wood N. W., Lees A. J. et al. (2002) Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125: 2248-2256
137. Healy D. G., Abou-Sleiman P. M., Valente E. M., Gilks W. P., Bhatia K., Quinn N. et al. (2004) DJ-1 mutations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 75: 144-145
138. Hedrich K., Djarmati A., Schafer N., Hering R., Wellenblock C., Weiss P. H. et al. (2004) DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology 62: 389-394
139. Gu W. J., Corti O., Araujo F., Hampe C., Jacquier S., Lucking C. B. et al. (2003) The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates. Neurobiol. Dis. 14: 357-364
140. Cookson M. R., Lockhart P. J., McLendon C., O'Farrell C., Schlossmacher M., Farrer M. J. (2003) RING finger 1 mutations in Parkin produce altered localization of the protein. Hum. Mol. Genet. 12: 2957-2965
141. Oliveira S. A., Scott W. K., Martin E. R., Nance M. A., Watts R. L., Hubble J. P. et al. (2003) Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann. Neurol. 53: 624-629
142. Hayashi S., Wakabayashi K., Ishikawa A., Nagai H., Saito M., Maruyama M. et al. (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord. 15: 884-888
143. Yamamura Y., Hattori N., Matsumine H., Kuzuhara S. and Mizuno Y. (2000) Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification. Brain. Dev. 22: S87-91
144. van de Warrenburg B. P., Lammens M., Lucking C. B., Denefle P., Wesseling P., Booij J. et al. (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56: 555-557
145. Morales B., Martinez A., Gonzalo I., Vidal L., Ros R., Gomez-Tortosa E. et al. (2002) Steele-Richardson-Olszewski syndrome in a patient with a single C212Y mutation in the parkin protein. Mov. Disord. 17: 1374-1380
146. Gouider-Khouja N., Larnaout A., Arnouri R., Sfar S., Belal S., Ben Hamida C. et al. (2003) Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism. Relat. Disord. 9: 247-251
147. Thobois S., Ribeiro M. J., Lohmann E., Durr A., Pollak P., Rascol O et al. (2003) Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. Arch. Neurol. 60: 713-718
148. Tassin J., Durr A., Bonnet A. M., Gil R., Vidailhet M., Lucking C. B. et al. (2000) Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 123: 1112-1121
149. Tan L. C., Tanner C. M., Chen R., Chan P., Farrer M., Hardy J. et al. (2003) Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov. Disord. 18: 758-763
150. van Duijn C. M., Dekker M. C., Bonifati V., Galjaard R. J., Houwing-Duistermaat J. J., Snijders P. J. et al. (2001) Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet. 69: 629-634
151. Bonifati V., Breedveld G. J., Squitieri F., Vanacore N., Brustenghi P., Harhangi B. S. et al. (2002) Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann. Neurol. 51: 253-256
152. Bonifati V., Rizzu P., van Baren M. J., Schaap O., Breedveld G. J., Krieger E. et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259
153. Abou-Sleiman P. M., Healy D. G., Quinn N., Lees A. J. and Wood N. W. (2003) The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54: 283-286
154. Hague S., Rogaeva E., Hernandez D., Gulick C., Singleton A., Hanson M. et al. (2003) Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann. Neurol. 54: 271-274
155. Honbou K., Suzuki N. N., Horiuchi M., Niki T., Taira T., Ariga H. et al. (2003) The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J. Biol. Chem. 278: 31380-31384
156. Tao X. and Tong L. (2003) Crystal structure of human DJ-1, a protein associated with early-onset Parkinson's disease. J. Biol. Chem. 278: 31372-31379
157. Wilson M. A., Collins J. L., Hod Y., Ringe D. and Petsko G. A. (2003) The 1,1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc. Natl. Acad. Sci. USA 100: 9256-9261
158. Macedo M. G., Anar B., Bronner I. F., Cannella M., Squitieri F., Bonifati V. et al. (2003) The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum. Mol. Genet. 12: 2807-2816
159. Miller D. W., Ahmad R., Hague S., Baptista M. J., Canet-Aviles R., McLendon C. et al. (2003) L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem. 278: 36588-36595
160. Moore D. J., Zhang L., Dawson T. M. and Dawson V. L. (2003) A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J. Neurochem. 87: 1558-1567
161. Rizzu P., Hinkle D. A., Zhucareva V., Bonifati V., Severijnen L.-A., Martinez D. et al. (2004) DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia. Ann. Neurol. 55: 113-118
162. Neumann M., Muller V., Gorner K., Kretzschmar H. A., Haass C. and Kahle P. J. (2004) Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta. Neuropathol. 107: 489-496
163. Valente E. M., Bentivoglio A. R., Dixon P. H., Ferraris A., Ialongo T., Frontali M. et al. (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68: 895-900
164. Valente E. M., Brancati F., Ferraris A., Graham E. A., Davis M. B., Breteler M. M. et al. (2002) PARK6-linked parkinsonism occurs in several European families. Ann Neurol 51: 14-18
165. Khan N. L., Valente E. M., Bentivoglio A. R., Wood N. W., Albanese A., Brooks D. J. et al. (2002) Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol. 52: 849-853
166. Bentivoglio A. R., Cortelli P., Valente E. M., Ialongo T., Ferraris A., Elia A. et al. (2001) Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov. Disord. 16: 999-1006
167. Valente E. M., Abou-Sleiman P. M., Caputo V., Muqit M. M., Harvey K., Gispert S. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. Published online 15 April 2004; 10.1126/science.1096284
168. Hampshire D. J., Roberts E., Crow Y., Bond J., Mubaidin A., Wriekat A. L. et al. (2001) Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J. Med. Genet. 38: 680-682
169. Najim al-Din A. S., Wriekat A., Mubaidin A., Dasouki M. and Hiari M. (1994) Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta. Neurol. Scand. 89: 347-352
170. DeStefano A. L., Golbe L. I., Mark M. H., Lazzarini A. M., Maher N. E., Saint-Hilaire M. et al. (2001) Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology 57: 1124-1126
171. Pankratz N., Nichols W. C., Uniacke S. K., Halter C., Rudolph A., Shults C. et al. (2003) Significant linkage of Parkinson disease to chromosome 2q36-37. Am. J. Hum. Genet. 72: 1053-1057
172. Pankratz N., Nichols W. C., Uniacke S. K., Halter C., Murrell J., Rudolph A. et al. (2003) Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum. Mol. Genet. 12: 2599-2608
173. Li Y. J., Scott W. K., Hedges D. J., Zhang F., Gaskell P. C., Nance M. A. et al. (2002) Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 70: 985-993
174. Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2: 492-501
175. Zoghbi H. Y. and Botas J. (2002) Mouse and fly models of neurodegeneration. Trends. Genet. 18: 463-471
176. Clayton D. F. and George J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends. Neurosci. 21: 249-254
177. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W. H., Castillo P. E. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25: 239-252
178. Kobayashi H., Kruger R., Markopoulou K., Wszolek Z., Chase B., Taka H. et al. (2003) Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. Brain. 126: 32-42
179. George J. M., Jin H., Woods W. S. and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 15: 361-372
180. Davidson W. S., Jonas A., Clayton D. F. and George J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273: 9443-9449
181. Conway K. A., Harper J. D. and Lansbury P. T. Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39: 2552-2563
182. Serpell L. C., Berriman J., Jakes R., Goedert M. and Crowther R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA 97: 4897-4902
183. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J. et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511
184. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M. et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95: 6448-6453
185. Sousa M. M., Cardoso I., Fernandes R., Guimaraes A. and Saraiva M. J. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159: 1993-2000
186. Muchowski P. J. Ning K., D'Souza-Schorey C., Fields S. (2002) Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl. Acad. Sci. USA 99: 727-732
187. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S. et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539
188. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97: 571-576
189. Krishnan S., Chi E. Y., Wood S. J., Kendrick B. S., Li C., Garzon-Rodriguez W. et al. (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry. 42: 829-837
190. Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. and Selkoe D. J. (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 37: 583-595
191. Lee H. J., Shin S. Y., Choi C., Lee Y. H. and Lee S. J. (2002) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277: 5411-5417
192. Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L. and Di Monte D. A. (2002) The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277: 1641-1644
193. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301-1306
194. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J. M., Farer M. and Wolozin B. (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20: 6048-6054
195. Yamin G., Glaser C. B., Uversky V. N. and Fink A. L. (2003) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J. Biol. Chem. 278: 27630-27635
196. Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M. et al. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21: 8053-8061
197. Rideout H. J., Larsen K. E., Sulzer D. and Stefanis L. (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78: 899-908
198. Junn E., Ronchetti R. D., Quezado M. M., Kim S. Y., Mouradian M. M. (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA 100: 2047-2052
199. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S. et al. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160-164
200. Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I. et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989
201. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V. M. et al. (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277: 49071-49076
202. Golts N., Snyder H., Frasier M., Theisler C., Choi P. and Wolozin B. (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277: 16116-16123
203. Uversky V. N., Li J., Souillac P., Millett I. S., Doniach S., Jakes R. et al. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 277: 11970-11978
204. Hashimoto M., Rockenstein E., Mante M., Mallory M. and Masliah E (2001) beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32: 213-223
205. Giasson B. I., Forman M. S., Higuchi M., Golbe L. I., Graves C. L., Kotzbauer P. T. et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640
206. Arima K., Hirai S., Sunohara N., Aoto K., Izumiyama Y., Ueda K. et al. (1999) Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein- epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain. Res. 843: 53-61
207. Ishizawa T., Mattila P., Davies P., Wang D. and Dickson D. W. (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J. Neuropathol. Exp. Neurol. 62: 389-397
208. Rockenstein E., Hansen L. A., Mallory M., Trojanowski J. Q., Galasko D. and Masliah E. (2001) Altered expression of the synuclein family mRNA in Lewy, body and Alzheimer's disease. Brain. Res. 914: 48-56
209. Wirdefeldt K., Bogdanovic N., Westerberg L., Payami H., Schalling M. and Murdoch G. (2001) Expression of alpha-synuclein in the human brain: relation to Lewy body disease. Brain. Res. Mol. Brain. Res. 92: 58-65
210. Ghee M. and Fournier A., Mallet J. (2000) Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75: 2221-2224
211. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A. and Wolozin B. (2003) Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278: 11753-11759
212. Bennett M. C., Bishop J. F., Leng Y., Chock P. B., Chase T. N. and Mouradian M. M. (1999) Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274: 33855-33858
213. Webb J. L., Ravikumar B., Atkins J., Skepper J. N. and Rubinsztein D. C. (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278: 25009-25013
214. Tofaris G. K., Layfield R., Spillantini M. G. (2001) alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509: 22-26
215. Ancolio K., Alves da Costa C., Ueda K. and Checler F. (2000) Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha- synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285: 79-82
216. Mishizen-Eberz A. J., Guttmann R. P., Giasson B. I., Day G. A., Hodara R., Ischiropoulos H. et al. (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86: 836-847
217. Iwata A., Maruyama M., Akagi T., Hashikawa T., Kanazawa I., Tsuji S. et al. (2003) Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synuclein-opathies. Hum. Mol. Genet. 12: 2625-2635.
218. Kim S. J., Sung J. Y., Um J. W., Hattori N., Mizuno Y., Tanaka K. et al. (2003) Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. J. Biol. Chem. 278: 41890-41899.
219. Bence N. F., Sampat R. M., Kopito R. R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555
220. Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E. et al. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10: 919-926
221. Hsu L. J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M. et al. (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157: 401-410
222. Gosavi N., Lee H. J., Lee J. S., Patel S. and Lee S. J. (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277: 48984-48992
223. Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C. et al. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 7812-7819
224. Xu J., Kao S. Y., Lee F. J., Song W., Jin L. W. and Yankner B. A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8: 600-606
225. Lee F. J., Liu F., Pristupa Z. B., Niznik H. B. (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15: 916-926
226. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H. K. and Brundin P. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277: 38884-38894
227. Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1346-1349
228. Richfield E. K., Thiruchelvam M. J., Cory-Slechta D. A., Wuertzer C., Gainetdinov R. R., Caron M. G. et al. (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175: 35-48
229. Dauer W., Kholodilov N., Vila M., Trillat A. C., Goodchild R., Larsen K. E. et al. (2002) Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99: 14524-14529
230. Schluter O. M., Fornai F., Alessandri M. G., Takamori S., Geppert M., Jahn R. et al. (2003) Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism in mice. Neuroscience 118: 985-1002
231. Lotharius J. and O'Malley K. L. (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275: 38581-38588
232. Ko L., Mehta N. D., Farrer M., Basson C., Hussey J., Yen S. et al. (2000) Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75: 2546-2554
233. Kanda S., Bishop J. F., Eglitis M. A., Yang Y. and Mouradian M. M. (2000) Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97: 279-284
234. Lee M., Hyun D., Halliwell B. and Jenner P. (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76: 998-1009
235. Junn E. and Mouradian M. M. (2002) Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320: 146-150
236. Tabrizi S. J., Orth M., Wilkinson J. M., Taanman J. W., Warner T. T., Cooper J. M. et al. (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxieity. Hum. Mol. Genet. 9: 2683-2689
237. Hashimoto M., Hsu L. J., Rockenstein E., Takenouchi T., Mallory M. and Masliah E. (2002) alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 277: 11465-11472
238. Alves Da Costa C., Paitel E., Vincent B. and Checler F. (2002) Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. J. Biol. Chem. 277: 50980-50984
239. Manning-Bog A. B., McCormack A. L., Purisai M. G., Bolin L. M. and Di Monte D. A. (2003) Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23: 3095-3099
240. Swerdlow R. H., Parks J. K., Cassarino D. S., Binder D. R., Bennett J. P. Jr, Di Iorio G. et al. (2001) Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Exp Neurol 169: 479-485
241. McNaught K. S., Shashidharan P., Perl D. P., Jenner P. and Olanow C. W. (2002) Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 16: 2136-2148
242. Kopito R. R. (2000) Aggresomes, inclusion bodies and protein aggregation. Trends. Cell. Biol. 10: 524-530
243. Junn E., Lee S. S., Suhr U. T. and Mouradian M. M. (2002) Parkin accumulation in aggresomes due to proteasome impairment. J. Biol. Chem. 277: 47870-47877
244. Fink A. L. (1999) Chaperone-mediated protein folding. Physiol. Rev. 79: 425-449
245. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. and Bonini N. M. (2002) Chaperone suppression of alpha-synuclein toxieity in a Drosophila model for Parkinson's disease. Science 295: 865-868
246. Cummings C. J., Reinstein E., Sun Y., Antalffy B., Jiang Y., Ciechanover A. et al. (1999) Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 24: 879-892
247. Morett E. and Bork P. (1999) A novel transactivation domain in parkin. Trends. Biochem. Sci. 24: 229-231
248. Tashiro M., Okubo S., Shimotakahara S., Hatanaka H., Yasuda H., Kainosho M. et al. (2003) NMR structure of ubiquitin-like domain in parkin: gene product of familial Parkinson's disease. J. Biomol. NMR. 25: 153-156
249. Sakata E., Yamaguchi Y., Kurimoto E., Kikuchi J., Yokoyama S., Yamada S. et al. (2003) Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 4: 301-306
250. Upadhya S. C. and Hegde A. N. (2003) A potential proteasome-interacting motif within the ubiquitin-like domain of parkin and other proteins. Trends. Biochem. Sci. 28: 280-283
251. Tsai Y. C., Fishman P. S., Thakor N. V. and Oyler G. A. (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 278: 22044-22055
252. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25: 302-305
253. Imai Y., Soda M., Takahashi R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275: 35661-35664
254. Zhang Y., Gao J., Chung K. K., Huang H., Dawson V. L. and Dawson T. M. (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 97: 13354-13359
255. Glickman M. H. and Ciechanover A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82: 373-428
256. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. and Takahashi R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105: 891-902
257. Choi P., Ostrerova-Golts N., Sparkman D., Cochran E., Lee J. M. and Wolozin B. (2000) Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport. 11: 2635-2638
258. Conaway R. C., Brower C. S. and Conaway J. W. (2002) Emerging roles of ubiquitin in transcription regulation. Science 296: 1254-1258
259. Itier J. M., Ibanez P., Mena M. A., Abbas N., Cohen-Salmon C., Bohme G. A. et al. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet 12: 2277-2291
260. Goldberg M. S., Fleming S. M., Palacino J. J., Cepeda C., Lam H. A., Bhatnagar A. et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278: 43628-43635
261. Pawlyk A. C., Giasson B. I., Sampathu D. M., Perez F. A., Lim K. L., Dawson V. L. et al. (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 278: 48120-48128
262. Choi P., Snyder H., Petrucelli L., Theisler C., Chong M., Zhang Y. et al. (2003) SEPT5_v2 is a parkin-binding protein. Brain. Res. Mol. Brain. Res. 117: 179-189
263. Huynh D. P., Scoles D. R., Nguyen D. and Pulst S. M. (2003) The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet. 12: 2587-2597
264. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R. et al. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269
265. Fallon L., Moreau F., Croft B. G., Labib N., Gu W. J. and Fon E. A. (2002) Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J. Biol. Chem. 277: 486-491
266. Staropoli J. F., McDermott C., Martinat C., Schulman B., Demireva E. and Abeliovich A. (2003) Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron. 37: 735-749
267. Corti O., Hampe C., Koutnikova H., Darios F., Jacquier S., Prigent A. et al. (2003) The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum. Mol. Genet. 12: 1427-1437
268. Ren Y., Zhao J. and Feng J. (2003) Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J. Neurosci. 23: 3316-3324
269. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K. I. et al. (2002) CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell. 10: 55-67
270. Petrucelli L., O'Farrell C., Lockhart P. J., Baptista M., Kehoe K., Vink L. et al. (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 36: 1007-1019
271. Yang Y., Nishimura I., Imai Y., Takahashi R. and Lu B. (2003) Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron. 37: 911-924
272. Muqit M. M., Davidson S. M., Payne Smith M. D., MacCormac L. P., Kahns S., Jensen P. H. et al. (2004) Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival. Hum. Mol. Genet. 13: 117-135
273. Ardley H. C., Scott G. B., Rose S. A., Tan N. G., Markham A. F. and Robinson P. A. (2003) Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol. Biol. Cell. 14: 4541-4556
274. Greene J. C., Whitworth A. J., Kuo I., Andrews L. A., Feany M. B. and Pallanck L. J. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA 100: 4078-4083
275. Jenner P. (2003) Oxidative stress in Parkinson's disease. Ann. Neurol. 53: S26-S36
276. Darios F., Corti O., Lucking C. B., Hampe C., Muriel M. P., Abbas N. et al. (2003) Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12: 517-526
277. Hyun D. H., Lee M., Hattori N., Kubo S., Mizuno Y., Halliwell B. et al. (2002) Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses and the proteasome. J. Biol. Chem. 277: 28572-28577
278. Palacino J. J., Sagi D., Goldberg M. S., Krauss S., Motz C., Klose J. et al. (2004) Mitochondrial dysfunction and oxidative damage in Parkin-deficient mice. J. Biol. Chem. 279: 18614-18622